# EDGAR Filing Document

**Accession Number:** 0000072444
**File Stem:** 0001213900-26-063174
**Filing Date:** 2026-6
**Character Count:** 8746
**Document Hash:** a62f947714ad34b52fb8aa7409cbc66b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-063174.hdr.sgml**: 20260601

**ACCESSION NUMBER**: 0001213900-26-063174

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20260601

**DATE AS OF CHANGE**: 20260601

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vaxart, Inc.
- **CENTRAL INDEX KEY:** 0000072444
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 591212264
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35285
- **FILM NUMBER:** 261047489

**BUSINESS ADDRESS:**
- **STREET 1:** 310 UTAH AVENUE, SUITE 150
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **BUSINESS PHONE:** (650) 550-3500

**MAIL ADDRESS:**
- **STREET 1:** 310 UTAH AVENUE, SUITE 150
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aviragen Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20160413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biota Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20121113

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NABI BIOPHARMACEUTICALS
- **DATE OF NAME CHANGE:** 20100719

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ☒ <br> Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to § 240.14a-12

**VAXART, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

☒ No fee required. <br> ☐ Fee paid previously with preliminary materials <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

From the Company's website *Vote.Vaxart.com* as of June 1, 2026:

![](ea029290701_img2.jpg)

![](ea029290701_img3.jpg)

![](ea029290701_img4.jpg)

How to Vote Michael Fein Campaign Management (855) 264 - 1527 Aaron Palash / Adam Pollack 3oele Frank Wilkinson Brimme Katcher (212) 355 - 4449 P ivacy Policy Eva iI Address Submit A ART Home Our Qualified Nominees FAQs Resources Why should I vote "FOR" ALL 6 of Vaxart's director nominees on the WHITE proxy card? • As this critical moment for the Company, con in i , execution, and disciplined oversight matter . • The Board and management team are managing several key priorities that we believe have the potential to yield tremendous value . • Our Board has been intentionally curated with directors that bring the specialized qualifications and judgment to guide vaccine development, regulator rate financing and commercialization planning . • Co ective Vaxar directors have been involved in the development and commercialization of multiple approved therapies and vaccines, successfully guided public biotechnology companies, overseen major acquisitions and worked directly with global regulator agencies and pharmaceutical partners . • be firmly believe that replacing any of our directors as this state would put important progress and the value o our investment at risk . What do you think about the retail shareholder nominees? • Our Nominating and Governance Committee and Board reviewed the retail shareholder nominees and determined that none of when are qualified ojoin our Board. • They have no experience overseeing a clinical - stage biotechnology company, advancing vaccine prop ra ms, managing regulatory processes or raising capital for a public company. • be recognize that the shareholders' three nominees are professionals in their respective fields. But their careers have nothing to do with Vaxart, our business or the specific regulators with which we interact. • The may to achieve positive results in to have people — like Vaxart' directors — with the relevant qualifications directly overseeing the Company at this critical time. What should I do with the proxy materials I received from the retail shareholder nominees? What if I've already voted for the retail shareholder nominees? Can I change my vote? • Only your latest validly executed prop card counts. be urge you to vote the WHITE prop card today "FOR" ALL o Vaxar 's nominees and WITHHOLD on the retail shareholder nominees. What happens if I don't vote? • ou do not vote, your voice will not be heart. Vote the WHITE prop card today "FOR" ALL o Vaxar 's nominees and WITH HOLD on the retail shareholder nominees. Who can I contact for more information or if I have questions about how to vote? • ou have questions or require assistance with voting your share please contact Vaxar 's prop solicitor, Campaign Managements as (8SS) 2641527. What differentiates Vaxart's oral vaccine platform and what impact could it have? Do the Board and management believe near - term stock price appreciation is a priority, and how are you squaring that with your longer - term strategy? How does management think about balancing dilution risk with the need to preserve flexibility across multiple programs? When would Vaxart consider raising capital? Why is Steven Lo the right person to lead the Company as CEO? What is the primary focus of the upcoming sentinel readout? When will we get more information? • The primal purpose of this Sentinel cohort in to evaluate label and immuno enicity. • While there will be e icac - related measures reported, this 4O - person sentinel cohort will not provide a statistically significant comparison between Vaxar 's oral pill and mRNA vaccines. • More definitive insights are expected to come from our main cohort of approximately S,OOO participants, which is designed and powered to evaluate relative e icac and safety. • be anticipate the primal e icacy and safety data reado from this larger group in early 2027. Does Vaxart plan to use the capital from Lincoln Park for a specific purpose? What's the plan and timeline for relisting on NASDAQ? How would Vaxart achieve that? How did recent Board changes align with shareholder interests?

![](ea029290701_img5.jpg)

![](ea029290701_img6.jpg)

**About Vaxart** 

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

**Cautionary Language Concerning Forward-Looking Statements** 

**Important Additional Information and Where to Find It**

Vaxart has filed a definitive proxy statement and form of white proxy card with the U.S. Securities and Exchange Commission (the "SEC") in connection with its solicitation of proxies for the 2026 Annual Meeting of Stockholders (the "Annual Meeting"). STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH, OR FURNISHED TO, THE SEC IN CONNECTION WITH THE ANNUAL MEETING CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. Stockholders are able to obtain the Company's proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC's website at www.sec.gov. Copies are also available at no charge at the Company's website at https://investors.vaxart.com/financials-filings/sec-filings.

**Investor Contact**

Michael Fein

Campaign Management

(855) 264-1527

**Media Contact**

Aaron Palash / Adam Pollack

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449